Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator

• Үндсэн зохиолчид: Jia Miao (Зохиогч), Ping Fu (Зохиогч), Shuang Ren (Зохиогч), Chao Hu (Зохиогч), Ying Wang (Зохиогч), Chengfeng Jiao (Зохиогч), Ping Li (Зохиогч), Yu zhao (Зохиогч), Cui Tang (Зохиогч), Yuli Qian (Зохиогч), Rong Yang (Зохиогч), Yanli Dong (Зохиогч), Jing Rong (Зохиогч), Yaohui Wang (Зохиогч), Xiaowei Jin (Зохиогч), Yu Sun (Зохиогч), Li Chen (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Wiley, 2022-02-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract Dorzagliatin is a novel allosteric glucokinase activator targeting both pancreatic and hepatic glucokinase currently under clinical investigation for treatment of type 2 diabetes (T2D). This study aimed to investigate the effect of renal impairment (RI) on dorzagliatin's pharmacokineti...